Authors
Sunil R, Vasudevan S, Praveen Gopi, Narain Kewlani, Rakesh Ranjan
Department of Urology, Government Medical College Trivandrum, Kerala
Abstract
Medical College Hospital, Thiruvananthapuram.
Study population: Patients who underwent TURBT and HPR came as high grade and low grade urothelial carcinoma
Study period: 2014-2017
Number of patients: 52
Exclusion Criteria:
- Immunocompromised
- Uncontrolled diabetes mellitus
- Gross haematuria
- h/o BCG sepsis
- Total incontinence
Methodology
Patents after receiving induction therapy of 6 cycles of BCG immunotherapy were followed up weekly as maximum symptoms occur during initial weeks and the data was collected, tabulated and analysed.
OBSERVATIONS
- In our study we observed patients who received intravesical BCG following TURBT and HPR came as high grade and low grade urothelial carcinoma during the study period 2014-2017. We collected around 52 patients who took BCG and observed the following adverse reactions. Out of 52 patients we observed on primary analysis 13 had no symptoms and in the rest of the patients most common symptoms are irritative symptoms like urgency (23.1%, frequency (28.8%) dysuria (48.1%) fever (53.8%), myalgia (25%) and abdominal pain (19.2%) and the rarest complications like arthritis (3.8%), rash (1.9%), conjunctivitis (1.9%), hepatitis (1.9%) epididymo orchitis (1.9%) see table 1. The timing of onset of symptoms was also noted see figure 1.
- Secondary analysis was done using sex, age category as exposure factors and post BCG symptoms as outcome factors.